-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE FOURTH INDICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-05-09
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 20252025-05-02
-
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H4-TARGETED ANTIBODY-DRUG CONJUGATE HS-200892025-05-01
-
GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME2025-04-28
-
FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 (UPDATED)2025-04-28
-
NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM2025-04-28
-
NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REQUEST FORM2025-04-28
-
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20242025-04-28
-
ANNUAL REPORT 20242025-04-28
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF HENGMEIDA (IBREXAFUNGERP TABLETS) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2025-04-25
-
Next Day Disclosure Return2025-04-22
-
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER2025-04-17
